Sort
30,917 grants matching “tumor microenvironment”
Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer.
$566,752Rahul Suresh Shinde · Wistar Institute · R37 · FY2025 · CA
Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
$566,680Stacey Deleria Finley · University Of Southern California · U01 · FY2020 · CA
Characterization and Functional Analysis of Breast Cancer Secreted Exosomes in Ma
$566,658David Charles Lyden · Weill Medical Coll Of Cornell Univ · U01 · FY2016 · CA
Optimization of High Frequency Irreversible Electroporation (H-FIRE) for tumor ablation and immune system activation in pancreatic cancer applications
$566,567Irving C Allen · Virginia Polytechnic Inst And St Univ · R01 · FY2023 · CA
Effects of chronic pubertal stressors on mammary gland biology and cancer risk
$566,425Matthew J Brady · University Of Chicago · R01 · FY2021 · CA
Modulation of ferroptotic cell death by mitochondrial calcium signaling
$566,379Haitao Wen · Ohio State University · R01 · FY2025 · CA
Modulation of ferroptotic cell death by mitochondrial calcium signaling
$566,379Haitao Wen · Ohio State University · R01 · FY2024 · CA
Role of circular RNA CDR1as in melanoma
$566,315Eva Hernando · New York University School Of Medicine · R01 · FY2021 · CA
Changing Contraceptive Patterns and Ovarian Cancer Risk
$566,293Kathryn L Terry · Brigham And Women'S Hospital · R01 · FY2022 · CA
Delineating Functional Immunity via Image-Guided PET
$566,226Nerissa Therese Viola · Wayne State University · R37 · FY2018 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment
$566,138William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment
$566,138William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
Bottlebrush polymer prodrugs for targeted delivery of combination therapies and in vivo imaging of pharmacological response
$566,131Jeremiah Allen Johnson · Massachusetts Institute Of Technology · R01 · FY2024 · CA
Molecular signatures for liver cancer diagnosis and treatment stratification
$566,077Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
The identification of human hepatocellular carcinoma metastasis genes
$566,077Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
$565,969Waldemar Debinski · Wake Forest University Health Sciences · R01 · FY2024 · CA
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors
$565,936Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2023 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer
$565,924David Tsai Ting · Massachusetts General Hospital · R01 · FY2022 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer
$565,924David Tsai Ting · Massachusetts General Hospital · R01 · FY2023 · CA
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer
$565,815Kristin J Lastwika · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
$565,690David D Tran · University Of Southern California · R01 · FY2025 · CA
(7) Novel imaging devices for measurement and control of tumor microenvironments
$565,675John S Condeelis · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · CA
Improving response durability after CAR T cell therapy for multiple myeloma
$565,591Michael C. Milone · University Of Pennsylvania · P01 · FY2024 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
$565,439Timothy R Donahue · University Of California Los Angeles · R01 · FY2023 · CA
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
$565,310Tyler J. Curiel · University Of Texas Hlth Science Center · R01 · FY2021 · CA